Additionally, BRCA2 mutation has been identified in 2.5-5.3% of aggressive prostate cancers (85, 86) and the standardized incidence ratio of prostate cancer in males known to carry a pathogenic BRCA2 mutation was found to be 4.45 (87). This evidence concerns the gene BRCA2 and prostate carcinoma.